Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target decreased by Truist Financial from $20.00 to $18.00 in a research report released on Wednesday, FlyOnTheWall reports. A number of other equities analysts also recently commented on ALLO. EF Hutton Acquisition Co. I reaffirmed a buy rating and set a $15.00 price objective on shares […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report)’s stock price traded up 6.3% during mid-day trading on Monday . The company traded as high as $5.78 and last traded at $5.76. 663,991 shares were traded during mid-day trading, a decline of 71% from the average session volume of 2,257,527 shares. The stock had previously closed at […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have assigned a buy recommendation to the company. […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) dropped 7.3% on Tuesday . The stock traded as low as $6.22 and last traded at $6.25. Approximately 343,732 shares changed hands during trading, a decline of 82% from the average daily volume of 1,961,051 shares. The stock had previously closed at $6.74. Analyst Ratings Changes ALLO has […]
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) issued its earnings results on Wednesday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05), Briefing.com reports. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.08 million. Allogene Therapeutics had a negative net […]